Fig. 1: Elevated N-acylethanolamines in chronic opioid users. | Neuropsychopharmacology

Fig. 1: Elevated N-acylethanolamines in chronic opioid users.

From: Endocannabinoids and related lipids linked to social exclusion in individuals with chronic non-medical prescription opioid use

Fig. 1

Individuals with chronic non-medical prescription opioid use (NMPOU; blue; triangles) showed significantly higher basal plasma levels of (a) anandamide (AEA), palmitoylethanolamide (PEA), and oleoylethanolamide (OEA) compared to drug-naïve healthy controls (white; diamonds), but no group difference was found for (b) 1-Stearoyl-2-arachidonoyl-sn-glycerol (SAG), linoleoyl ethanolamide (LEA), stearoyl ethanolamide (SEA), 2-arachidonylglycerol (2-AG), 2-oleoylglycerol (2-OG), arachidonic acid (AA). Bars represent means including individual data points, and error bars reflect standard error of the mean (SEM); corrected for age and sex. Significant p-values marked with p-values < 0.05*, p-values < 0.01**.

Back to article page